CLINICAL_TRIALS
trial_result
· 2014-07-31
Clinical Trial Update: EMD 521873 in Advanced Solid Tumors, MTD Finding [Phase 1]
Summary
Phase 1 study evaluating the maximum tolerated dose and safety of EMD 521873 in patients with Non-Hodgkin lymphoma; the trial is completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED